267 related articles for article (PubMed ID: 23275034)
1. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
Ward KK; Tancioni I; Lawson C; Miller NL; Jean C; Chen XL; Uryu S; Kim J; Tarin D; Stupack DG; Plaxe SC; Schlaepfer DD
Clin Exp Metastasis; 2013 Jun; 30(5):579-94. PubMed ID: 23275034
[TBL] [Abstract][Full Text] [Related]
2. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.
Shah NR; Tancioni I; Ward KK; Lawson C; Chen XL; Jean C; Sulzmaier FJ; Uryu S; Miller NL; Connolly DC; Schlaepfer DD
Gynecol Oncol; 2014 Jul; 134(1):104-11. PubMed ID: 24786638
[TBL] [Abstract][Full Text] [Related]
3. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth.
Tancioni I; Miller NL; Uryu S; Lawson C; Jean C; Chen XL; Kleinschmidt EG; Schlaepfer DD
Breast Cancer Res; 2015 Mar; 17():47. PubMed ID: 25880415
[TBL] [Abstract][Full Text] [Related]
4. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Stone RL; Baggerly KA; Armaiz-Pena GN; Kang Y; Sanguino AM; Thanapprapasr D; Dalton HJ; Bottsford-Miller J; Zand B; Akbani R; Diao L; Nick AM; DeGeest K; Lopez-Berestein G; Coleman RL; Lutgendorf S; Sood AK
Cancer Biol Ther; 2014 Jul; 15(7):919-29. PubMed ID: 24755674
[TBL] [Abstract][Full Text] [Related]
5. FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.
Tancioni I; Uryu S; Sulzmaier FJ; Shah NR; Lawson C; Miller NL; Jean C; Chen XL; Ward KK; Schlaepfer DD
Mol Cancer Ther; 2014 Aug; 13(8):2050-61. PubMed ID: 24899686
[TBL] [Abstract][Full Text] [Related]
6. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.
Tanjoni I; Walsh C; Uryu S; Tomar A; Nam JO; Mielgo A; Lim ST; Liang C; Koenig M; Sun C; Patel N; Kwok C; McMahon G; Stupack DG; Schlaepfer DD
Cancer Biol Ther; 2010 May; 9(10):764-77. PubMed ID: 20234191
[TBL] [Abstract][Full Text] [Related]
7. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.
Walsh C; Tanjoni I; Uryu S; Tomar A; Nam JO; Luo H; Phillips A; Patel N; Kwok C; McMahon G; Stupack DG; Schlaepfer DD
Cancer Biol Ther; 2010 May; 9(10):778-90. PubMed ID: 20234193
[TBL] [Abstract][Full Text] [Related]
8. Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion.
Sachdev S; Bu Y; Gelman IH
BMC Cancer; 2009 Jan; 9():12. PubMed ID: 19138410
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW
Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606
[TBL] [Abstract][Full Text] [Related]
10. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways.
Badgwell DB; Lu Z; Le K; Gao F; Yang M; Suh GK; Bao JJ; Das P; Andreeff M; Chen W; Yu Y; Ahmed AA; S-L Liao W; Bast RC
Oncogene; 2012 Jan; 31(1):68-79. PubMed ID: 21643014
[TBL] [Abstract][Full Text] [Related]
11. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Halder J; Kamat AA; Landen CN; Han LY; Lutgendorf SK; Lin YG; Merritt WM; Jennings NB; Chavez-Reyes A; Coleman RL; Gershenson DM; Schmandt R; Cole SW; Lopez-Berestein G; Sood AK
Clin Cancer Res; 2006 Aug; 12(16):4916-24. PubMed ID: 16914580
[TBL] [Abstract][Full Text] [Related]
12. The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
Serrels A; McLeod K; Canel M; Kinnaird A; Graham K; Frame MC; Brunton VG
Int J Cancer; 2012 Jul; 131(2):287-97. PubMed ID: 21823119
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
14. Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival.
Lim ST; Miller NL; Nam JO; Chen XL; Lim Y; Schlaepfer DD
J Biol Chem; 2010 Jan; 285(3):1743-53. PubMed ID: 19880522
[TBL] [Abstract][Full Text] [Related]
15. Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis.
Ozmadenci D; Shankara Narayanan JS; Andrew J; Ojalill M; Barrie AM; Jiang S; Iyer S; Chen XL; Rose M; Estrada V; Molinolo A; Bertotto T; Mikulski Z; McHale MC; White RR; Connolly DC; Pachter JA; Kuchroo VK; Stupack DG; Schlaepfer DD
Proc Natl Acad Sci U S A; 2022 Apr; 119(17):e2117065119. PubMed ID: 35467979
[TBL] [Abstract][Full Text] [Related]
16. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
[TBL] [Abstract][Full Text] [Related]
17. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line.
Pengetnze Y; Steed M; Roby KF; Terranova PF; Taylor CC
Biochem Biophys Res Commun; 2003 Sep; 309(2):377-83. PubMed ID: 12951060
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation.
Lane D; Goncharenko-Khaider N; Rancourt C; Piché A
Oncogene; 2010 Jun; 29(24):3519-31. PubMed ID: 20400979
[TBL] [Abstract][Full Text] [Related]
19. ERK activation and nuclear signaling induced by the loss of cell/matrix adhesion stimulates anchorage-independent growth of ovarian cancer cells.
Al-Ayoubi A; Tarcsafalvi A; Zheng H; Sakati W; Eblen ST
J Cell Biochem; 2008 Oct; 105(3):875-84. PubMed ID: 18726893
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma.
Judson PL; He X; Cance WG; Van Le L
Cancer; 1999 Oct; 86(8):1551-6. PubMed ID: 10526262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
